Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report
- 23 June 2021
- journal article
- research article
- Published by International Scientific Information, Inc. in The American Journal of Case Reports
- Vol. 22, e932924
- https://doi.org/10.12659/ajcr.932924
Abstract
Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report - Article abstract #932924Keywords
This publication has 11 references indexed in Scilit:
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell CarcinomaJAMA Oncology, 2020
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020Journal of the National Comprehensive Cancer Network, 2020
- Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinomaJournal for ImmunoTherapy of Cancer, 2019
- Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated ColitisJournal of Clinical Oncology, 2019
- Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With CancerJAMA Oncology, 2019
- Novel patterns of response under immunotherapyAnnals of Oncology, 2019
- Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLCCancer Immunology Research, 2018
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialThe Lancet Oncology, 2015
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010